ILab (ILAB(DRUGDISCOVERY) KS EQUITY)

Analysis

Health Care • South Korea

The company develops small molecule immune response modulating drugs to address unmet medical needs. It focuses on the development of oral, small-molecule tumor necrosis factor (TNF) therapies designed to offer low immunogenicity for the treatment of rheumatoid arthritis and related diseases.

Refresh

Focused

No publications yet

There aren’t any syndicated reports right now

Back to "All"

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00